J P Guastalla

537 total citations
14 papers, 312 citations indexed

About

J P Guastalla is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, J P Guastalla has authored 14 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 4 papers in Cancer Research and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in J P Guastalla's work include Cancer Treatment and Pharmacology (10 papers), Breast Cancer Treatment Studies (4 papers) and Advanced Breast Cancer Therapies (3 papers). J P Guastalla is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Breast Cancer Treatment Studies (4 papers) and Advanced Breast Cancer Therapies (3 papers). J P Guastalla collaborates with scholars based in France, Netherlands and United States. J P Guastalla's co-authors include Johan G. Brun, Pierre D. Delmas, F. Munoz, Cyrille B. Confavreux, A Fontana, P. Fumoleau, J. B. Vermorken, M. Clavel, Michel Fabbro and Adrianus C. Laan and has published in prestigious journals such as Cancer Research, British Journal of Cancer and Annals of Oncology.

In The Last Decade

J P Guastalla

14 papers receiving 304 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J P Guastalla France 9 213 84 73 57 51 14 312
Laia Garrigós Spain 9 322 1.5× 63 0.8× 46 0.6× 51 0.9× 177 3.5× 35 402
Jungsil Ro South Korea 5 258 1.2× 79 0.9× 96 1.3× 29 0.5× 18 0.4× 6 299
Jeffrey C. Goh Australia 11 167 0.8× 34 0.4× 109 1.5× 26 0.5× 91 1.8× 35 376
C. Caroti Italy 9 330 1.5× 23 0.3× 138 1.9× 69 1.2× 72 1.4× 21 419
Carol Ward United Kingdom 8 110 0.5× 34 0.4× 52 0.7× 13 0.2× 32 0.6× 13 259
Sarah Morgan United States 6 231 1.1× 46 0.5× 150 2.1× 6 0.1× 108 2.1× 12 421
A. Astone Italy 9 233 1.1× 32 0.4× 52 0.7× 8 0.1× 82 1.6× 22 336
Ryan Gillihan United States 5 182 0.9× 85 1.0× 114 1.6× 77 1.4× 59 1.2× 12 361
Charles R. Sikes United States 10 175 0.8× 84 1.0× 122 1.7× 20 0.4× 262 5.1× 12 402
Fabio Catalano Italy 11 142 0.7× 48 0.6× 61 0.8× 9 0.2× 119 2.3× 37 329

Countries citing papers authored by J P Guastalla

Since Specialization
Citations

This map shows the geographic impact of J P Guastalla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J P Guastalla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J P Guastalla more than expected).

Fields of papers citing papers by J P Guastalla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J P Guastalla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J P Guastalla. The network helps show where J P Guastalla may publish in the future.

Co-authorship network of co-authors of J P Guastalla

This figure shows the co-authorship network connecting the top 25 collaborators of J P Guastalla. A scholar is included among the top collaborators of J P Guastalla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J P Guastalla. J P Guastalla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Pivot, Xavier, Gilles Romieu, Hervé Bonnefoi, et al.. (2012). Phare Trial Results Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer. Annals of Oncology. 23. ixe2–ixe2. 13 indexed citations
2.
Pivot, Xavier, Gilles Romieu, Hervé Bonnefoi, et al.. (2012). Abstract S5-3: PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Cancer Research. 72(24_Supplement). S5–3. 24 indexed citations
3.
4.
5.
Peters, Godefridus J., M. Clavel, Paul Noordhuis, et al.. (2007). Clinical Phase I and Pharmacology Study of Gemcitabine (2', 2'-Difluorodeoxycytidine) Administered in a Two-Weekly Schedule. Journal of Chemotherapy. 19(2). 212–221. 36 indexed citations
6.
Confavreux, Cyrille B., A Fontana, J P Guastalla, et al.. (2007). Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone. 41(3). 346–352. 88 indexed citations
7.
Kerbrat, Pierre, Henri Roché, Jacques Bonneterre, et al.. (2007). Epirubicin–vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial. British Journal of Cancer. 96(11). 1633–1638. 11 indexed citations
8.
Aapro, Matti, F.H. van Wijk, M.E.L. van der Burg, et al.. (2003). Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group. European Journal of Cancer. 39(8). 1141–1143. 1 indexed citations
9.
Mahé, M.-A., et al.. (1999). A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.. PubMed. 5(10 Suppl). 3249s–3253s. 45 indexed citations
10.
Vermorken, J. B., et al.. (1997). Phase I study of gemcitabine using a once every 2 weeks schedule. British Journal of Cancer. 76(11). 1489–1493. 21 indexed citations
11.
Pujade-Lauraine, Éric, J P Guastalla, B. Weber, et al.. (1997). Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.. PubMed. 24(5 Suppl 15). S15–30. 8 indexed citations
12.
Lhommé, C., Pierre Kerbrat, C Lejeune, et al.. (1996). Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.. PubMed. 23(5 Suppl 12). 48–54. 8 indexed citations
13.
Merrouche, Yacine, G. Catimel, Paul Rebattu, et al.. (1994). A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy. Annals of Oncology. 5(6). 549–551. 9 indexed citations
14.
Clavel, M., et al.. (1989). [Chemotherapy of cancer of the breast in the metastatic phase].. PubMed. 76(1). 75–85. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laia Garrigós Breakdown of academic impact, for papers by Jungsil Ro Breakdown of academic impact, for papers by Jeffrey C. Goh Breakdown of academic impact, for papers by C. Caroti Breakdown of academic impact, for papers by Carol Ward Breakdown of academic impact, for papers by Sarah Morgan Breakdown of academic impact, for papers by A. Astone Breakdown of academic impact, for papers by Ryan Gillihan Breakdown of academic impact, for papers by Charles R. Sikes Breakdown of academic impact, for papers by Fabio Catalano
Rankless by CCL
2026